About Us
Mission RNAi Management Team Board of Directors Scientific Advisory Board
Management Team
Intradigm is led by a strong senior management team with proven track record in drug development and successful team leadership.
Dr. Azab joined Intradigm in July 2006. He brings more than 20 years of experience in pharmaceutical drug development. Dr. Azab’s prior appointment was Chief Medical Officer and Executive VP of R&D at QLT Inc, in Vancouver, BC, Canada. Dr. Azab also worked as Entrepreneur In Residence (EIR) for Ventures West, one of Canada’s leading venture capital firms in Technology & Life Sciences. His past positions included leadership of medical oncology at Sanofi Pharmaceuticals (now Sanofi-Aventis) working near Paris, France, and leadership of the clinical drug development in oncology at Zeneca Pharmaceuticals (now Astra Zeneca) in the company’s R&D facility in Macclesfield, England. During his career, he led drug development programs that resulted in the approval and marketing of seven different new chemical entities in the therapeutic areas of oncology, gastroenterology, urology, and ophthalmology including Casodex®, Arimidex®, Faslodex®, Photofrin®, and Visudyne®. Dr. Azab received his medical degree from Cairo University in 1979. He practiced as a medical oncologist at Institute Gustave Roussy, Villejuif, France where he received post-graduate training and degrees from the University of Paris-Sud and the University of Pierre and Marie Curie. He authored more than 100 scientific papers, abstracts, and book reviews.
Dr. Azab also holds an MBA degree with distinction from the Richard Ivey School of Business, University of Western Ontario in Canada. He is a member of the board for Xenon Pharma Inc.
Dr. Chamow joined Intradigm in November 2006 bringing 19 years of experience in the pharmaceutical biotechnology industry with emphasis on process development and manufacturing. Dr. Chamow was most recently Vice President, Process Sciences, at Genitope Corporation, a San Francisco Bay Area company developing antibody-based cancer vaccines. Earlier, Dr. Chamow was Vice President of Process Sciences at Abgenix, Inc., (now Amgen) where he built the company’s process sciences department and helped to lead the design and construction of Abgenix’ award-winning production facility in Fremont, CA. Prior to Abgenix, he served as Director of Biopharmaceutical Development at Scios, Inc., (acquired by J&J), and as a scientist and senior scientist in process development at Genentech, Inc, where he served for 11 years.
Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health. Dr. Chamow is author or co-author of more than 40 scientific publications and patents and co-editor of a 1999 book entitled ‘Antibody Fusion Proteins‘.
Dr. Haworth came to Intradigm in May 2007 having spent the previous 15 years in senior business development roles at several leading biotechnology companies including Genencor International, COR Therapeutics and Affymax/Affymetrix, among others. In these positions, he led the identification and negotiation of numerous collaborative and licensing agreements with a range of global and regional pharmaceutical companies. Most recently serving as vice president, business development at Codexis, Inc., Dr. Haworth successfully led the company’s strategic efforts to partner its innovative biocatalyst technology platform with pharmaceutical and biotechnology companies around the world. He possesses deep deal–making expertise that spans establishing discovery and development partnerships, technology and product in– and out–licensing, mergers and acquisitions, and financing support
Dr. Haworth earned his J.D. from Stanford University Law School and his Ph.D. in biochemistry from the University of Manchester in the U.K. He also received his bachelor’s degree with first class honors in physiology and biochemistry from the University of Southampton in the U.K.
Mr. Riley joined Intradigm in August 2006. Mike is leading the business operations, legal department and intellectual property.
Mr. Riley brings with him over ten years of intellectual property and international business experience. Most recently he held various positions in Europe and the US with Amgen, Abgenix and Celltech Group PLC. He obtained his JD with distinction from University of North Dakota School of law, and his M Sc from school of medicine, department of biochemistry and molecular biology.
Dr. Yang joined Intradigm in September 2006. Prior to joining Intradigm, Dr. Yang was Senior Director of Cancer Pharmacology at Abgenix (now Amgen). While at Abgenix, he was the project team leader for VectibixTM (panitumumab) and played a key role in discovery, development and BLA submission of VectibixTM. Dr. Yang was also Senior Director of the Oncology Program team responsible for setting strategy and managing Abgenix oncology project portfolio. He was in charge of managing collaborations with corporate partners including the oncology collaboration with AstraZeneca. He joined Abgenix in 1995 as one of the founding scientists and built the company’s preclinical development capability for both oncology and inflammation.
Dr. Yang received his medical degree from Beijing Medical University, China and was awarded his doctorate in Immunology from University of Bern, Switzerland. He did his postdoctoral training at Department of Microbiology and Immunology, Stanford University. Dr. Yang was also a postdoctoral fellow at Department of Inflammation and Allergy, Novartis. He has published more than 40 papers in peer-reviewed scientific journals and is inventor on over 15 issued and pending patents.
Dr. Zalipsky joined Intradigm in May 2007 with 20 years of experience in the pharmaceutical and biotechnology industry. He comes to Intradigm following eight–year tenure with ALZA Corporation (J&J Company) during which he established and managed programs focused on delivery of biopharmaceuticals, PEGylated proteins, and targeted delivery of liposomes. Prior to his work with ALZA, he held key technology positions with SEQUUS Pharmaceuticals and Enzon Inc., while also serving as a visiting associate professor in the chemistry department of Rutgers University. Dr. Zalipsky possesses broad drug delivery expertise that spans several important areas including chemistry of peptides, polymers for bio-medical application, bioconjugates with drugs, peptides/proteins, saccharides, lipids/liposomes, and nanoparticles. He has co–authored over 80 papers, is listed as an inventor on over 40 U.S. patents and currently serves on editorial advisory boards of several technical journals.
Dr. Zalipsky received his Ph.D. in chemistry from the University of Minnesota, Minneapolis. He earned both a master’s degree in chemistry and bachelor’s degrees in chemistry and biochemistry from the Hebrew University of Jerusalem.
|
